Atrial Fibrillation Burden and Long-term Risk of Thromboembolic Complications- the FinCV-4 Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-01

Study Completion Date

2025-01-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study explores the association of symptomatic episodes of atrial fibrillation (AF) occurrence and long-term risk of thromboembolic complications in a retrospective setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)

NCT04645537

Atrial Fibrillation

COMPLETED

Fibrosis, Inflammation and Brain Health in Atrial Fibrillation.

NCT03816865

Atrial Fibrillation Stroke

COMPLETED

Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (From the DAF-ESUS Registry)

NCT04761315

Fibrillation, Atrial

COMPLETED

Treatment of Atrial Fibrillation in Finland

NCT01990105

Atrial Fibrillation

COMPLETED

Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE

NCT05293080

Acute Ischemic Stroke Atrial Fibrillation

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study population consists of the FinCV-dataset, which includes 7660 acute cardioversions for atrial fibrillation. The electronic patient records of FinCV-study patients are reviewed to collect data on anticoagulation, number of cardioversions as well as mortality and stroke data. We seek to explore the possible association between the frequency of AF paroxysms in low stroke risk patients and the occurrence of death, stroke and major bleed as well as the net clinical benefit of anticoagulation. Data collection is performed by reviewing electronic patient records.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Stroke, Ischemic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No oral anticoagulation

Patients without oral anticoagulation for AF

No interventions assigned to this group

Oral anticoagulation

Patients with long term oral anticoagulation

Anticoagulation Therapy

Intervention Type DRUG

Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anticoagulation Therapy

Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* primary diagnosis of atrial fibrillation (ICD-10 code I48)
* Cardioversion for acute (\<48 h) atrial fibrillation
* \>18 years of age
* living within the catchment area of the hospital

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No